Lung adenocarcinoma
Conditions
Interventions
Modeling team and validation team:None
Sponsors
The Second Affiliated Hospital of Hainan Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age: Age at surgery >=18 years old; 2. Diagnosis: Patients received surgical resection, and primary lung adenocarcinoma was confirmed by postoperative paraffin pathology; 3. Imaging data: Contrast-enhanced chest CT was performed in our hospital before surgery (generally within 1 week), and the original thin-slice (slice thickness <= 3 mm) DICOM-format imaging data are complete and available; 4. Molecular pathological data: Test results of EGFR gene mutation status based on surgically resected specimens (test methods may include amplification refractory mutation system-PCR, next-generation sequencing, etc.); 5. Pathological subtype data: Complete postoperative pathological reports containing information on predominant pathological subtypes classified according to the 2015 WHO classification criteria or the IASLC/ATS/ERS multidisciplinary classification (especially the identification of high-risk subtypes such as micropapillary and solid subtypes); 6. Baseline data: Accessible basic clinical information including at least gender, age and smoking history.
Exclusion criteria
Exclusion criteria: 1. Image quality issues: Preoperative CT images have artifacts that severely affect lesion observation and delineation (such as respiratory motion artifacts and metal implant artifacts), excessively low image resolution, or the scan range does not fully cover the entire lung. 2. Previous treatment history: Any form of anti-tumor therapy administered for the pulmonary lesion before surgery, including but not limited to puncture biopsy, radiofrequency ablation, radiotherapy, chemotherapy, targeted therapy or immunotherapy. 3. Interference from comorbidities: Previous or concurrent history of malignant tumors in other organs (excluding basal cell carcinoma of the skin). 4. Incomplete information: Missing key data, such as absence of postoperative pathological reports, unavailable EGFR test results, lack of preoperative enhanced CT images, or severely incomplete clinical baseline data precluding analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EGFR gene mutation status; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological subtypes of lung adenocarcinoma; | — |
Countries
China
Contacts
Public ContactPeng Dongge
The Second Affiliated Hospital of Hainan Medical University
Outcome results
None listed